help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by GROSSET, J.
Right arrow Articles by JI, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GROSSET, J.
Right arrow Articles by JI, B.

Am. J. Respir. Crit. Care Med., Volume 157, Number 5, May 1998, 1436-1440

Once-weekly Rifapentine-containing Regimens for Treatment of Tuberculosis in Mice

JACQUES GROSSET, NACER LOUNIS, CHANTAL TRUFFOT-PERNOT, RICHARD J. O'BRIEN, MARIO C. RAVIGLIONE, and BAOHONG JI

Bactériologie et Hygiène, Faculté de Médecine Pitié-Salpêtrière, Paris, France; Research and Evaluation Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; and Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland

The bactericidal activities of several once-weekly rifapentine (P)-containing combination regimens against Mycobacterium tuberculosis, and their ability to prevent the selection of rifampin (R)-resistant mutants, were compared with those of the standard six-times-weekly regimen consisting of R, isoniazid (H), and pyrazinamide (Z) in a mouse experiment. Mice were infected intravenously with 1.3 × 107 cfu of M. tuberculosis strain H37Rv, and 8 wk of treatment began on Day 14 after infection, when mice were randomly allocated to an untreated control group and nine treatment groups of 30 mice each. At the end of 8 wk of treatment, all the tested regimens showed promising bactericidal activities. Once-weekly P alone was less bactericidal than six-times-weekly R alone; likewise, the once-weekly P-containing combined regimens were less bactericidal than the six-times-weekly standard regimen. However, the difference in killing was about 1 log10, which represented only a fraction of the overall 4 log10 to 5 log10 magnitude of killing effects. The addition of streptomycin (S) improved the bactericidal effect of once-weekly PHZ, and the effect of once-weekly PHZS was further enhanced when it was preceded by 2 wk of daily HZS. The latter regimen achieved the same level of activity as the standard six-times-weekly regimen. All of the once-weekly P-containing combined regimens were able to prevent the selection of R-resistant mutants, whereas monotherapy with R or P selected resistant mutants in approximately 50% of animals.




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
N. Lounis, A. Bentoucha, C. Truffot-Pernot, B. Ji, R. J. O'Brien, A. Vernon, G. Roscigno, and J. Grosset
Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice
Antimicrob. Agents Chemother., December 1, 2001; 45(12): 3482 - 3486.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
A. M. Lenaerts, S. E. Chase, and M. H. Cynamon
Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model
Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3167 - 3168.
[Abstract] [Full Text]

Home page
 J Antimicrob ChemotherHome page
N. Rastogi, K. S. Goh, M. Berchel, and A. Bryskier
Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG
J. Antimicrob. Chemother., October 1, 2000; 46(4): 565 - 570.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. M. Shoen, S. E. Chase, M. S. DeStefano, T. S. Harpster, A. J. Chmielewski, and M. H. Cynamon
Evaluation of Rifalazil in Long-Term Treatment Regimens for Tuberculosis in Mice
Antimicrob. Agents Chemother., June 1, 2000; 44(6): 1458 - 1462.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. DANIEL, N. LOUNIS, B. JI, R. J. O'BRIEN, A. VERNON, L. J. GEITER, M. SZPYTMA, C. TRUFFOT-PERNOT, G. HEJBLUM, and J. GROSSET
Antituberculosis Activity of Once-weekly Rifapentine-containing Regimens in Mice . Long-term Effectiveness with 6- and 8-Month Treatment Regimens
Am. J. Respir. Crit. Care Med., May 1, 2000; 161(5): 1572 - 1577.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
A. M. J. A. Lenaerts, S. E. Chase, A. J. Chmielewski, and M. H. Cynamon
Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice
Antimicrob. Agents Chemother., October 1, 1999; 43(10): 2356 - 2360.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
E. Miyazaki, R. E. Chaisson, and W. R. Bishai
Analysis of Rifapentine for Preventive Therapy in the Cornell Mouse Model of Latent Tuberculosis
Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2126 - 2130.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society 		  Red In Translatin